NEW YORK, March 14, 2017 /PRNewswire/ --
Biotechnology is this morning's featured industry on Stock-Callers.com,
Shares in California headquartered Gilead Sciences Inc. saw a slight drop of 0.13%, ending Monday's trading session at $68.10. The stock recorded a trading volume of 8.42 million shares. The Company's shares have gained 3.83% in the last one month. The stock is trading 4.29% below its 50-day moving average. Moreover, shares of Gilead Sciences, which discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and Middle East, have a Relative Strength Index (RSI) of 38.91.
On February 22nd, 2017, Gilead Sciences Canada, Inc. announced, effective February 28th, 2017, that Ontario will provide public access to EPCLUSA™ (sofosbuvir/velpatasvir) tablets, the first once-daily pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus infection. This listing will support patients to access curative therapy, and will advance Canada's efforts to achieving its World Health Organization commitment to eliminate hepatitis C by 2030.
On March 09th, 2017, research firm UBS resumed its 'Neutral' rating on the Company's stock while revising its previous target price from $118 a share to $72 a share. Visit us today and download your complete report on GILD for free at:
California headquartered Exelixis Inc.'s stock rose 0.97%, closing the day at $21.85 with a total trading volume of 4.39 million shares. The Company's shares have surged 29.21% in the previous three months and 46.55% since the start of this year. The stock is trading 10.95% and 60.13% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Exelixis, which engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer, have an RSI of 52.53.
On February 28th, 2017, research firm Stifel downgraded the Company's stock rating from 'Buy' to 'Hold' while revising its previous target price from $21 a share to $22 a share.
On March 06th, 2017, Exelixis announced that the US Food & Drug Administration (FDA) has granted orphan drug designation to cabozantinib for the treatment of hepatocellular carcinoma (HCC). A pivotal phase-3 trial (CELESTIAL) of cabozantinib is ongoing in patients with advanced HCC, and Exelixis has guided that data from the trial are expected in 2017. The complimentary research report on EXEL can be accessed at:
On Monday, shares in California headquartered Mast Therapeutics Inc. recorded a trading volume of 3.10 million shares. The stock ended the day 2.90% lower at $0.11. The Company's shares have advanced 22.78% since the start of this year, and are trading below their 50-day moving average by 12.53%. Furthermore, shares of Mast Therapeutics, which develops therapies for serious or life-threatening diseases with significant unmet needs, have an RSI of 34.17.
On March 06th, 2017, Mast Therapeutics reported that its wholly-owned subsidiary, Aires Pharmaceuticals, Inc., has entered into an agreement with the University of Pittsburgh related to a Phase-1/2 open-label safety and proof of concept clinical trial of the Company's lead product candidate, AIR001, for the treatment of Pseudomonas aeruginosa (P. aeruginosa) infection in cystic fibrosis patients. Mast's subsidiary will provide study drug and nebulizers for the study, but no direct financial support. Register for free on Stock-Callers.com and download the PDF research report on MSTX at:
Maryland headquartered Novavax Inc.'s stock dropped 1.37%, finishing yesterday's session at $1.44 with a total trading volume of 3.06 million shares. The Company's shares have advanced 9.09% in the last one month, 0.70% in the previous three months, and 14.29% since the start of this year. The stock is trading above its 50-day moving average by 3.67%. Additionally, shares of Novavax, which focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants, have an RSI of 50.48.
On February 27th, 2017, Novavax reported a net loss of $57.1 million, or $0.21 per share, for Q4 2016 compared to a net loss of $78.8 million, or $0.29 per share, for Q4 2015. Novavax revenue in Q4 2016 decreased 8% to $5.4 million compared to $5.9 million for Q4 2015. Get free access to your research report on NVAX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...View All